Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

ROCHE HOLDING LTD.
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 53 071 M
EBIT 2017 18 345 M
Net income 2017 11 388 M
Debt 2017 9 074 M
Yield 2017 3,53%
Sales 2018 55 386 M
EBIT 2018 19 458 M
Net income 2018 12 266 M
Debt 2018 4 836 M
Yield 2018 3,72%
P/E ratio 2017 17,77
P/E ratio 2018 16,54
EV / Sales2017 4,18x
EV / Sales2018 3,93x
Capitalization 212 786 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
12:25p ROCHE : raises outlook for 2017 following strong launches
07/27 CHUGAI PHARMACEUTICAL REPORTS FINDIN : their identification and pharmacological ..
07/27 ROCHE HOLDING LTD. : UPCOMING DEADLINE: Lundin Law PC Announces Securities Class..
07/27 ROCHE HOLDING LTD. : Levi & Korsinsky, LLP Reminds Shareholders of Roche Holding..
07/27 ROCHE : antibody becomes first of its kind authorised for blood cancer
07/27 SENSEONICS : Roche joins quest to create closed loop insulin device
07/27 AstraZeneca slump dominates European shares on busy earnings day
07/27 ROCHE : NICE backs Cancer Drugs Fund support for Roche`s Gazyvaro
07/27 ROCHE : reports strong performance in the first half of 2017
07/26 ROCHE : Positive Phase III Results of Genentech’s Actemra (Tocilizumab) fo..
More news
Sector news : Pharmaceuticals - NEC
08:48aDJASTRAZENECA : Shares Plummet On Drug News -- WSJ
07/27 S&P 500 declines with transports; oil extends recent rally
07/27DJADRs End Mostly Lower; Anheuser-Busch InBev, AstraZeneca Trade Actively
07/27 AstraZeneca pain weighs on FTSE, Diageo makes merry after results
07/27 AstraZeneca lung cancer failure sparks 16 percent share fall
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 281  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.220 038
JOHNSON & JOHNSON13.66%352 757
NOVARTIS9.04%222 032
ROCHE HOLDING LTD.4.21%220 038
PFIZER1.26%195 864
MERCK AND COMPANY8.19%169 033